Mediolanum International Funds Ltd Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Mediolanum International Funds Ltd increased its stake in Regeneron Pharmaceuticals by 646.7% during Q1, owning 33,220 shares valued at approximately $21.17 million.
• Regeneron Pharmaceuticals reported Q1 earnings of $8.22 per share, missing expectations by $0.61, while revenues were down 3.7% year-over-year at $3.03 billion.
• Analysts have mixed ratings on Regeneron, with 16 buy ratings and decreased price targets from various brokerages, reflecting a consensus rating of "Moderate Buy."

Mediolanum International Funds Ltd increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 646.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,220 shares of the biopharmaceutical company's stock after purchasing an additional 28,771 shares during the quarter. Mediolanum International Funds Ltd's holdings in Regeneron Pharmaceuticals were worth $21,173,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Proficio Capital Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 30.5% in the fourth quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 72 shares during the period. American Assets Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $427,000. Quantbot Technologies LP boosted its stake in shares of Regeneron Pharmaceuticals by 266.7% during the fourth quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company's stock valued at $376,000 after purchasing an additional 384 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $330,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN traded up $2.21 during trading on Wednesday, hitting $560.36. 197,437 shares of the stock were exchanged, compared to its average volume of 1,111,474. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a 50 day simple moving average of $540.67 and a 200 day simple moving average of $606.53. The firm has a market cap of $60.50 billion, a price-to-earnings ratio of 14.28, a P/E/G ratio of 2.10 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $9.55 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analyst Ratings Changes

Several equities research analysts have recently commented on REGN shares. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $700.00 to $580.00 in a report on Friday, May 30th. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research note on Friday, May 30th. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.